SCHEMBL3145642

SCHEMBL3145642

N#Cc1ccc(C#CC(=O)N2CCN(c3nc(-c4ccc(Cl)cc4)cs3)CC2)cc1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 7/20 0.59
LMNA P02545 5/20 0.59
MAPK1 P28482 5/20 0.59
SMN1; SMN2 Q16637 5/20 0.59
TSHR P16473 1/20 0.57
NPSR1 Q6W5P4 1/20 0.57
MEN1 O00255 4/20 0.53
KMT2A Q03164 4/20 0.53
HTT P42858 4/20 0.53
ALDH1A1 P00352 2/20 0.53
HSD17B10 Q99714 2/20 0.53
RAB9A P51151 4/20 0.50
NPC1 O15118 3/20 0.50
EGFR P00533 2/20 0.46
KDR P35968 2/20 0.46
ERBB4 Q15303 2/20 0.46
ERBB2 P04626 1/20 0.45
IGF1R P08069 1/20 0.45
AR P10275 1/20 0.44
SPR P35270 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3156292 0.82 RAB9A (0.63) MAPTLMNAMAPK1SMN1; SMN2NPSR1
SCHEMBL18711344 0.81 MAPT (0.56) MAPTLMNAMAPK1SMN1; SMN2TSHR
SCHEMBL3151283 0.80 RAB9A (0.57) MAPTLMNAMAPK1SMN1; SMN2NPSR1
SCHEMBL3145638 0.80 MAPK1 (0.52) MAPTLMNAMAPK1SMN1; SMN2TSHR
SCHEMBL18702016 0.78 MAPT (0.53) MAPTLMNAMAPK1SMN1; SMN2TSHR
SCHEMBL3160612 0.77 LMNA (0.57) MAPTLMNAMAPK1SMN1; SMN2MEN1
SCHEMBL18711653 0.77 MAPT (0.76) MAPTLMNAMAPK1SMN1; SMN2TSHR
SCHEMBL3146638 0.76 MAPT (0.57) MAPTLMNAMAPK1SMN1; SMN2TSHR
SCHEMBL14046467 0.74 CHEK1 (0.57) MAPTLMNAMAPK1SMN1; SMN2MEN1
SCHEMBL18702156 0.74 MAPT (0.71) MAPTLMNAMAPK1SMN1; SMN2TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1765816-B1 SUBSTITUTED 1-PROPIOLYLPIPERAZINES HAVING AN AFFINITY FOR THE MGLUR5 RECEPTOR IN ORDER TO TREAT PAINFUL CONDITIONS GRUENENTHAL GMBH (DE) 2010-03-10 EP claimed
US-7300939-B2 Substituted 1-propiolylpiperazine compounds, their preparation and use GRUENENTHAL GMBH (DE) 2007-11-27 US claimed
US-20070112011-A1 Substituted 1-propiolylpiperazine compounds, their preparation and use GRUENENTHAL GMBH (DE) 2007-05-17 US claimed
EP-1765816-B1 SUBSTITUTED 1-PROPIOLYLPIPERAZINES HAVING AN AFFINITY FOR THE MGLUR5 RECEPTOR IN ORDER TO TREAT PAINFUL CONDITIONS GRUENENTHAL GMBH (DE) 2010-03-10 EP disclosed
US-7300939-B2 Substituted 1-propiolylpiperazine compounds, their preparation and use GRUENENTHAL GMBH (DE) 2007-11-27 US disclosed
US-20070112011-A1 Substituted 1-propiolylpiperazine compounds, their preparation and use GRUENENTHAL GMBH (DE) 2007-05-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070112011-A1 Substituted 1-propiolylpiperazine compounds, their preparation and use GRM5, GRIK5, GRM1 MAPT 3334/4885LMNA 2615/4885MAPK1 1290/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.